Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2

Exclusion Criteria15

• Patients who plan to receive diabetes treatment at other hospitals.
• Patients who have used an automated insulin delivery system or sensor-augmented pump within 3 months prior to screening.
• Patients who refuse to use continuous glucose monitoring or insulin pumps, or refuse data upload and remote monitoring.
• Patients with severe cardiovascular, cerebrovascular, hepatic, or renal diseases; uncontrolled systemic diseases, thyroid diseases; autoimmune diseases; or malignancies.
• Patients diagnosed with hematologic or bleeding disorders.
• Patients who have received red blood cell transfusions or erythropoiesis-stimulating agents within 3 months prior to screening.
• Patients who have used any oral, injectable, or intravenous corticosteroids within 8 weeks prior to screening, or who plan to use corticosteroids during the trial.
• Patients with severe skin diseases that may affect the application sites of continuous glucose monitoring or insulin pump patches.
• Patients with auditory or visual impairments.
• Patients with alcohol or drug abuse.
• Patients who plan to receive blood transfusions during the study period.
• Patients who plan to undergo elective surgery requiring general anesthesia or dialysis during the study period.
• Pregnant women, women planning to become pregnant within 1 year of the study, or women who are breastfeeding.
• Patients who are currently participating in or have participated in other drug or device trials within the last 2 weeks.
• Patients who, in the investigator's opinion, are not suitable for participation in this clinical trial, such as those with a history of vision impairment, eating disorders, celiac disease, etc.